1. Конради А.О. Ключевые достижения в комбинированной антигипертензивной терапии последних лет. Артериальная гипертензия. 2012; 18 (6): 1–5.
2. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation and treatment – a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): 1403–19.
3. Sudano I, Flammer AJ, Roas S et al. Nonsteroidal antiinflammatory drugs, acetaminophen and hypertension. Curr Hypertens Rep 2012; 14 (4): 304–9.
4. Sowers JR, White WB, Pitt B et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161–8.
5. Mancia G, Backer De G, Dominiczak A et al. ESH-ESC task force on the management of arterial hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25 (9): 1751–62.
6. Mancia G, Laurent S, Agabiti-Rosei E et al. European society of hypertension. Reappraisal of European guidelines on hypertension management – a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121–58.
7. Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359 (23): 2417–28.
8. Yusuf S, Teo KK, Pogue J et al. ONTARGET Investigators Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547–59.
9. Parving HH, Brenner BM, McMurray JJ et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367 (23): 2204–13.
10. Malacco E, Omboni S, Volpe M et al. ESPORT Study Group. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens 2010; 28 (11): 2342–50.
11. Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol 2007; 21 (2): 181–90.
12. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–91.
13. Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005; 46 (5): 585–93.
14. Haller H, Ito S, Izzo JL et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.
15. Ikeda H, Hamamoto Y, Honjo S et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009; 83 (1): 117–8.
16. Robles NR. Calcium antagonists and renal failure: new properties for new generations. Med Hypotheses Res 2006; 3 (2): 709–25.
17. Carmines PK, Navar LG. Disparate effects of Ca channel blockers on afferent and efferent arteriolar responses to ANG II. Am J Physiol 1989; 256: f1015–20.
18. Loutzenhiser R, Epstein M. Renal hemodynamic effects of calcium antagonists. In: M.Epstein, R.Loutzenhiser (ed.). Calcium Antagonists and the Kidney 1990. Philadelphia, Hanley & Belfus; p. 33–74.
19. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545–50.
20. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996; 50: 684–92.
21. Dworkin LD. Effects of calcium channel blockers on glomerular injury on experimental glomerular injury. J Am Soc Nephrol 1990; 1: s21–7.
22. Griffin KA, Picken MM, Bakris GI, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999; 55: 1849–60.
23. Praga M, Fernandez Andrade C, Luño J et al. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomised clinical trial. Nephrol Dial Transplant 2003; 18: 1806–13.
24. Crepaldi G, Carta Q, Deferrari G et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998; 21: 104–10.
25. Herlitz H, Harris K, Risler T et al. The effect of an ACE inhibitor and a calcium antagonist in the progression of renal disease. The Nephros Study. Nephrol Dial Transplant 2001; 16: 2158–65.
26. Dalla Vestra M et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL Study (Diabetes, Ipertensione, Albuminuria, Lercanidipina). Diab Nutr Metab 2004; 17: 259–66.
27. Bobrie G, Frank M, Azizi M et al. Sequential nephron blockade vs sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012; 30 (8): 1656–64.
28. Esler MD, Krum H, Schlaich M et al. Renal sympathetic denervation in patients with treatment resistant hypertension (Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903–9.

А.В.Родионов

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ

________________________________________________

A.V.Rodionov

I.M.Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation